Literature DB >> 24768623

Analytical performance of newly developed multiplex human papillomavirus genotyping assay using Luminex xMAP™ technology (Mebgen™ HPV Kit).

Satoru Ozaki1, Kana Kato2, Yukiko Abe2, Hirotaka Hara3, Hiroshi Kubota3, Kaneyuki Kubushiro4, Ei Kawahara5, Masaki Inoue6.   

Abstract

Regional differences in human papillomavirus (HPV) genotypes and the presence of mixed HPV infections may affect adversely the efficacy of the HPV vaccine. Therefore, a simple and high-throughput HPV genotyping system is required. Recently, a novel HPV genotyping kit (the Mebgen™ HPV kit) was developed. This kit uses multiplex PCR and Luminex xMAP™ technology to detect 13 types of high-risk HPVs and an internal control in a 96-well format. In the present study, the analytical performance of the kit was examined using HPV plasmid DNA. All 13 types of HPVs were detected with a minimum detection sensitivity of 250 copies/test, and highly specific signals were observed. HPV 16 plasmid was detected in samples containing mixtures with other HPV-type plasmids in ratios ranging from 1:1 to 1:1000. No cross reactivity was observed with DNA from 27 types of other infectious microbes. A clinical evaluation was carried out using cervical samples from 356 patients with persistent abnormal smears diagnosed at mass public health screenings for cervical cancer. The samples were preserved in Tacas™ medium until analysis. HPV was detected in 162 (45.5%) samples including 110 (67.9%) with single infections and 52 (32.1%) with multiple infections. The type distribution of the 13 high-risk HPVs was as follows: 28.4% HPV 16, 11.7% HPV 18, 6.8% HPV 31, 3.1% HPV 33, 3.7% HPV 35, 9.3% HPV 39, 1.9% HPV 45, 8.6% HPV 51, 37.0% HPV 52, 9.3% HPV 56, 16.7% HPV 58, 3.7% HPV 59, and 1.9% HPV 68. To evaluate sample stability over time, changes in the detection of HPV DNA derived from HeLa and SiHa cells were measured in 3 types of liquid-based cytology media. HPV DNA was detected in Tacas and Thinprep™ samples after storage at 4°C or 30°C for 4 weeks and within 1 week of collection in Surepath™ samples. These results suggest that this newly developed HPV genotyping kit is suitable for use in both clinical applications and large-scale epidemiological studies.
Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cervical cancer; HPV; HPV genotyping; Luminex; Multiplex PCR

Mesh:

Year:  2014        PMID: 24768623     DOI: 10.1016/j.jviromet.2014.04.010

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  10 in total

1.  Analytical Validation of a Personalized Medicine APOL1 Genotyping Assay for Nondiabetic Chronic Kidney Disease Risk Assessment.

Authors:  Jinglan Zhang; Anastasia Fedick; Stephanie Wasserman; Geping Zhao; Lisa Edelmann; Erwin P Bottinger; Ruth Kornreich; Stuart A Scott
Journal:  J Mol Diagn       Date:  2016-01-07       Impact factor: 5.568

2.  Multiplex genotyping of cytokine gene SNPs using fluorescence bead array.

Authors:  Jung-Pil Jang; In-Cheol Baek; Eun-Jeong Choi; Tai-Gyu Kim
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

3.  Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study.

Authors:  Takayuki Yoshino; Kei Muro; Kensei Yamaguchi; Tomohiro Nishina; Tadamichi Denda; Toshihiro Kudo; Wataru Okamoto; Hiroya Taniguchi; Kiwamu Akagi; Takeshi Kajiwara; Shuichi Hironaka; Taroh Satoh
Journal:  EBioMedicine       Date:  2015-02-14       Impact factor: 8.143

4.  Suspension Array for Multiplex Detection of Eight Fungicide-Resistance Related Alleles in Botrytis cinerea.

Authors:  Xin Zhang; Fei Xie; Baobei Lv; Pengxiang Zhao; Xuemei Ma
Journal:  Front Microbiol       Date:  2016-09-21       Impact factor: 5.640

5.  Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study.

Authors:  Hiroya Taniguchi; Wataru Okamoto; Kei Muro; Kiwamu Akagi; Hiroki Hara; Tomohiro Nishina; Takeshi Kajiwara; Tadamichi Denda; Shuichi Hironaka; Toshihiro Kudo; Taroh Satoh; Takeharu Yamanaka; Yukiko Abe; Yoshiyuki Fukushima; Takayuki Yoshino
Journal:  Neoplasia       Date:  2018-11-06       Impact factor: 5.715

6.  Diagnosing Alpha-1-Antitrypsin Deficiency Using A PCR/Luminescence-Based Technology.

Authors:  Martina Veith; Andreas Klemmer; Iker Anton; Rachid El Hamss; Noelia Rapun; Sabina Janciauskiene; Viktor Kotke; Christian Herr; Robert Bals; Claus Franz Vogelmeier; Timm Greulich
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-11-18

7.  Risk factors for HPV infection and high-grade cervical disease in sexually active Japanese women.

Authors:  Manako Yamaguchi; Masayuki Sekine; Sharon J B Hanley; Risa Kudo; Megumi Hara; Sosuke Adachi; Yutaka Ueda; Etsuko Miyagi; Takayuki Enomoto
Journal:  Sci Rep       Date:  2021-02-03       Impact factor: 4.379

8.  Human Papillomavirus and Risk of Head and Neck Squamous Cell Carcinoma in Iran.

Authors:  Abbas Karimi; Elham Mohebbi; Sandrine Mckay-Chopin; Hamideh Rashidian; Maryam Hadji; Vahideh Peyghambari; Maryam Marzban; Ahmad Naghibzadeh-Tahami; Mahin Gholipour; Farin Kamangar; Massimo Tommasino; Tarik Gheit; Kazem Zendehdel
Journal:  Microbiol Spectr       Date:  2022-06-16

9.  Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection.

Authors:  Risa Kudo; Manako Yamaguchi; Masayuki Sekine; Sosuke Adachi; Yutaka Ueda; Etsuko Miyagi; Megumi Hara; Sharon J B Hanley; Takayuki Enomoto
Journal:  J Infect Dis       Date:  2019-01-09       Impact factor: 5.226

10.  Long-term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real-world data.

Authors:  Megumi Kurosawa; Masayuki Sekine; Manako Yamaguchi; Risa Kudo; Sharon J B Hanley; Megumi Hara; Sosuke Adachi; Yutaka Ueda; Etsuko Miyagi; Sayaka Ikeda; Asami Yagi; Takayuki Enomoto
Journal:  Cancer Sci       Date:  2022-02-14       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.